Healthcare

Records

Documents

Files attached to records under this subject. Downloads fetch the official source on click; nothing is stored here.

• Presuda Suda (treće vijeće) od 19. prosinca 2024.#Teva BV i Teva Finland Oy protiv Merck Sharp & Dohme LLC i Merck Sharp & Dohme LLC protiv Clonmel Healthcare Limited.#Zahtjev za prethodnu odluku – Lijekovi za humanu primjenu – Svjedodžba o dodatnoj zaštiti (SDZ) – Uredba (EZ) br. 469/2009 – Uvjeti za dobivanje SDZ-a za lijekove – Članak 3. točka (a) – Pojam ‚proizvod zaštićen temeljnim patentom koji je na snazi’ – Članak 3. točka (c) – Pojam ‚proizvod koji je predmet SDZ-a’ – Kriteriji za ocjenu.#Spojeni predmeti C-119/22 i C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Wyrok Trybunału (trzecia izba) z dnia 19 grudnia 2024 r.#Teva BV i Teva Finland Oy przeciwko Merck Sharp & Dohme LLC i Merck Sharp & Dohme LLC przeciwko Clonmel Healthcare Limited.#Odesłanie prejudycjalne – Produkty lecznicze stosowane u ludzi – Dodatkowe świadectwo ochronne (DŚO) – Rozporządzenie (WE) nr 469/2009 – Warunki uzyskania DŚO dla produktów leczniczych – Artykuł 3 lit. a) – Pojęcie „produktu chronionego patentem podstawowym pozostającym w mocy” – Artykuł 3 lit. c) – Pojęcie „produktu będącego przedmiotem DŚO” – Kryteria oceny.#Sprawy połączone C-119/22 i C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Απόφαση του Δικαστηρίου (τρίτο τμήμα) της 19ης Δεκεμβρίου 2024.#Teva BV και Teva Finland Oy κατά Merck Sharp & Dohme LLC και Merck Sharp & Dohme LLC κατά Clonmel Healthcare Limited.#Προδικαστική παραπομπή – Φάρμακα που προορίζονται για ανθρώπινη χρήση – Συμπληρωματικό πιστοποιητικό προστασίας – Κανονισμός (ΕΚ) 469/2009 – Όροι χορήγησης ΣΠΠ για τα φάρμακα – Άρθρο 3, στοιχείο αʹ – Έννοια του “προϊόντος που προστατεύεται με ισχύον κύριο δίπλωμα ευρεσιτεχνίας” – Άρθρο 3, στοιχείο γʹ – Έννοια του “προϊόντος που αποτελεί αντικείμενο ΣΠΠ” – Κριτήρια εκτιμήσεως.#Συνεκδικασθείσες υποθέσεις C-119/22 και C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• 2024 m. gruodžio 19 d. Teisingumo Teismo (trečioji kolegija) sprendimas.#Teva BV ir Teva Finland Oy prieš Merck Sharp & Dohme LLC ir Merck Sharp & Dohme LLC prieš Clonmel Healthcare Limited.#Prašymas priimti prejudicinį sprendimą – Žmonėms skirti vaistai – Papildomos apsaugos liudijimas (PAL) – Reglamentas (EB) Nr. 469/2009 – Vaistų PAL gavimo sąlygos – 3 straipsnio a punktas – Sąvoka „produktas, apsaugotas galiojančiu pagrindiniu patentu“ – 3 straipsnio c punktas – Sąvoka „produktas, kuriam taikomas PAL“ – Vertinimo kriterijai.#Sujungtos bylos C-119/22 ir C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• A Bíróság ítélete (harmadik tanács), 2024. december 19.#Teva BV és társai kontra Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. és Clonmel Healthcare Limited.#Előzetes döntéshozatal – Emberi felhasználásra szánt gyógyszerek – Kiegészítő oltalmi tanúsítvány (SPC) – 469/2009/EK rendelet – Az SPC megszerzésének feltételei a gyógyszerek esetében – A 3. cikk a) pontja – A „hatályos alapszabadalom oltalma alatt álló termék” fogalma – A 3. cikk c) pontja – Az »SPC tárgyát képező termék« fogalma – Értékelési szempontok.#C-119/22. és C-149/22. sz. egyesített ügyek.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Hotărârea Curții (Camera a treia) din 19 decembrie 2024.#Teva BV și Teva Finland Oy împotriva Merck Sharp & Dohme LLC și Merck Sharp & Dohme LLC împotriva Clonmel Healthcare Limited.#Trimitere preliminară – Medicamente de uz uman – Certificat suplimentar de protecție (CSP) – Regulamentul (CE) nr. 469/2009 – Condiții de obținere a unui CSP pentru medicamente – Articolul 3 litera (a) – Noțiunea de «produs protejat de un brevet de bază în vigoare» – Articolul 3 litera (c) – Noțiunea de «produs care face obiectul unui CSP» – Criterii de apreciere.#Cauzele conexate C-119/22 și C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Tiesas spriedums (trešā palāta), 2024. gada 19. decembris.#Teva BV un Teva Finland Oy pret Merck Sharp & Dohme LLC un Merck Sharp & Dohme LLC pret Clonmel Healthcare Limited.#Lūgums sniegt prejudiciālu nolēmumu – Cilvēkiem paredzētas zāles – Papildu aizsardzības sertifikāts (PAS) – Regula (EK) Nr. 469/2009 – PAS zālēm saņemšanas nosacījumi – 3. panta a) punkts – Jēdziens “produkts, kuru aizsargā spēkā esošs pamatpatents” – 3. panta c) punkts – Jēdziens “produkts, kas ir PAS priekšmets” – Vērtējuma kritēriji.#Apvienotās lietas C-119/22 un C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sodba Sodišča (tretji senat) z dne 19. decembra 2024.#Teva BV in Teva Finland Oy proti Merck Sharp & Dohme LLC ter Merck Sharp & Dohme LLC proti Clonmel Healthcare Limited.#Predhodno odločanje – Zdravila za uporabo v humani medicini – Dodatni varstveni certifikat (DVC) – Uredba (ES) št. 469/2009 – Pogoji za pridobitev DVC za zdravila – Člen 3(a) – Pojem ‚izdelek varovan z veljavnim osnovnim patentom‘ – Člen 3(c) – Pojem ‚izdelek, ki je predmet DVC‘ – Merila presoje.#Združeni zadevi C-119/22 in C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentenza tal-Qorti tal-Ġustizzja (It-Tielet Awla) tad-19 ta’ Diċembru 2024.#Teva BV u Teva Finland Oy vs Merck Sharp & Dohme LLC u Merck Sharp & Dohme LLC vs Clonmel Healthcare Limited.#Rinviju għal deċiżjoni preliminari – Prodotti mediċinali għall-użu mill-bniedem – Ċertifikat ta’ protezzjoni supplimentari (ĊPS) – Regolament (KE) Nru 469/2009 – Kundizzjonijiet għall-kisba ta’ ĊPS għall-prodotti mediċinali – Artikolu 3(a) – Kunċett ta’ ‘prodott protett minn privattiva bażika fis-seħħ’ – Artikolu 3(c) – Kunċett ta’ ‘prodott li huwa s-suġġett ta’ ĊPS’ – Kriterji ta’ evalwazzjoni.#Kawżi magħquda C-119/22 u C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Решение на Съда (трети състав) от 19 декември 2024 г.#Teva BV и др. срещу Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. и Clonmel Healthcare Limited.#Преюдициално запитване — Лекарствени продукти за хуманна употреба — Сертификат за допълнителна закрила (СДЗ) — Регламент (ЕО) № 469/2009 — Условия за получаване на СДЗ за лекарствените продукти — Член 3, буква а) — Понятие за продукт, защитен с основен патент, който е в сила — Член 3, буква в) — Понятие за продукт, предмет на СДЗ — Критерии за преценка.#Съединени дела C-119/22 и C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Euroopa Kohtu otsus (kolmas koda), 19.12.2024.#Teva BV ja Teva Finland Oy versus Merck Sharp & Dohme LLC ja Merck Sharp & Dohme LLC versus Clonmel Healthcare Limited.#Eelotsusetaotlus – Inimtervishoius kasutatavad ravimid – Täiendava kaitse tunnistus – Määrus (EÜ) nr 469/2009 – Ravimite täiendava kaitse tunnistuse saamise tingimused – Artikli 3 punkt a – Mõiste „kehtiva aluspatendiga kaitstud toode“ – Artikli 3 punkt c – Mõiste „täiendava kaitse tunnistuse esemeks olev toode“ – Hindamiskriteeriumid.#Liidetud kohtuasjad C-119/22 ja C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentenza della Corte (Terza Sezione) del 19 dicembre 2024.#Teva BV e Teva Finland Oy contro Merck Sharp & Dohme LLC e Merck Sharp & Dohme LLC contro Clonmel Healthcare Limited.#Rinvio pregiudiziale – Medicinali per uso umano – Certificato protettivo complementare (CPC) – Regolamento (CE) n. 469/2009 – Condizioni di rilascio di un CPC per i medicinali – Articolo 3, lettera a) – Nozione di “prodotto protetto da un brevetto di base in vigore” – Articolo 3, lettera c) – Nozione di “prodotto oggetto di un CPC” – Criteri di valutazione.#Cause riunite C-119/22 e C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Domstolens dom (Tredje Afdeling) af 19. december 2024.#Teva BV og Teva Finland Oy mod Merck Sharp & Dohme LLC og Merck Sharp & Dohme LLC mod Clonmel Healthcare Limited.#Præjudiciel forelæggelse – humanmedicinske lægemidler – supplerende beskyttelsescertifikat – forordning (EF) nr. 469/2009 – betingelser for udstedelse af et supplerende beskyttelsescertifikat for lægemidler – artikel 3, litra a) – begrebet »produkt beskyttet ved et grundpatent, der er i kraft« – artikel 3, litra c) – begrebet »produkt, der er genstand for et supplerende beskyttelsescertifikat« – bedømmelseskriterier.#Forenede sager C-119/22 og C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Urteil des Gerichtshofs (Dritte Kammer) vom 19. Dezember 2024.#Teva BV und Teva Finland Oy gegen Merck Sharp & Dohme LLC und Merck Sharp & Dohme LLC gegen Clonmel Healthcare Limited.#Vorlage zur Vorabentscheidung – Humanarzneimittel – Ergänzendes Schutzzertifikat (ESZ) – Verordnung (EG) Nr. 469/2009 – Bedingungen für die Erteilung eines ESZ für Arzneimittel – Art. 3 Buchst. a – Begriff ‚durch ein in Kraft befindliches Grundpatent geschütztes Erzeugnis‘ – Art. 3 Buchst. c – Begriff ,Erzeugnis, für das ein ESZ erteilt wurde‘ – Beurteilungskriterien.#Verbundene Rechtssachen C-119/22 und C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Acórdão do Tribunal de Justiça (Terceira Secção) de 19 de dezembro de 2024.#Teva BV e Teva Finland Oy contra Merck Sharp & Dohme LLC e Merck Sharp & Dohme LLC contra Clonmel Healthcare Limited.#Reenvio prejudicial — Medicamentos para uso humano — Certificado complementar de proteção (CCP) — Regulamento (CE) n.° 469/2009 — Condições de obtenção de um CCP para os medicamentos — Artigo 3.°, alínea a) — Conceito de “produto protegido por uma patente de base em vigor” — Artigo 3.°, alínea c) — Conceito de “produto objeto de um CCP” — Critérios de apreciação.#Processos apensos C-119/22 e C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Rozsudok Súdneho dvora (tretia komora) z 19. decembra 2024.#Teva BV a Teva Finland Oy proti Merck Sharp & Dohme LLC a Merck Sharp & Dohme Corp. proti Clonmel Healthcare Limited.#Návrh na začatie prejudiciálneho konania – Humánne lieky – Dodatkové ochranné osvedčenie (DOO) – Nariadenie (ES) č. 469/2009 – Podmienky získania DOO na lieky – Článok 3 písm. a) – Pojem ‚výrobok chránený platným základným patentom‘ – Článok 3 písm. c) – Pojem ‚výrobok, na ktorý bolo vydané DOO‘ – Kritériá posúdenia.#Spojené veci C-119/22 a C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Arrest van het Hof (Derde kamer) van 19 december 2024.#Teva BV e.a. tegen Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. en Clonmel Healthcare Limited.#Prejudiciële verwijzing – Geneesmiddelen voor menselijk gebruik – Aanvullend beschermingscertificaat (ABC) – Verordening (EG) nr. 469/2009 – Voorwaarden voor de verkrijging van een ABC voor geneesmiddelen – Artikel 3, onder a) – Begrip ‚product beschermd door een van kracht zijnd basisoctrooi’ – Artikel 3, onder c) – Begrip ‚product waarvoor een ABC is verkregen’ – Beoordelingscriteria.#Gevoegde zaken C-119/22 en C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Domstolens dom (tredje avdelningen) av den 19 december 2024.#Teva BV och Teva Finland Oy mot Merck Sharp & Dohme LLC och Merck Sharp & Dohme LLC mot Clonmel Healthcare Limited.#Begäran om förhandsavgörande – Humanläkemedel – Tilläggsskydd – Förordning (EG) nr 469/2009 – Villkor för erhållande av tilläggsskydd för läkemedel – Artikel 3 a – Begreppet ’produkt som skyddas av ett gällande grundpatent’ – Artikel 3 c – Begreppet ’produkt för vilken tilläggsskydd har meddelats’ – Bedömningskriterier.#Förenade målen C-119/22 och C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Rozsudek Soudního dvora (třetího senátu) ze dne 19. prosince 2024.#Teva BV a Teva Finland Oy v. Merck Sharp & Dohme LLC a Merck Sharp & Dohme LLC v. Clonmel Healthcare Limited.#Řízení o předběžné otázce – Humánní léčivé přípravky – Dodatkové ochranné osvědčení (DOO) – Nařízení (ES) č. 469/2009 – Podmínky pro získání DOO pro léčivé přípravky – Článek 3 písm. a) – Pojem ‚výrobek chráněný platným základním patentem‘ – Článek 3 písm. c) – Pojem ‚výrobek, který je předmětem DOO‘ – Kritéria pro posouzení.#Spojené věci C-119/22 a C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Unionin tuomioistuimen tuomio (kolmas jaosto) 19.12.2024.#Teva BV ja Teva Finland Oy vastaan Merck Sharp & Dohme LLC ja Merck Sharp & Dohme LLC vastaan Clonmel Healthcare Limited.#Ennakkoratkaisupyyntö – Ihmisille tarkoitetut lääkkeet – Lisäsuojatodistus – Asetus (EY) N:o 469/2009 – Lääkkeiden lisäsuojatodistuksen saamisen edellytykset – 3 artiklan a alakohta – Käsite ”voimassa olevalla peruspatentilla suojattu tuote” – 3 artiklan c alakohta – Käsite ”lisäsuojatodistuksen saanut tuote” – Arviointiperusteet.#Yhdistetyt asiat C-119/22 ja C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentencia del Tribunal de Justicia (Sala Tercera) de 19 de diciembre de 2024.#Teva BV y Teva Finland Oy contra Merck Sharp & Dohme LLC y Merck Sharp & Dohme LLC contra Clonmel Healthcare Limited.#Procedimiento prejudicial — Medicamentos para uso humano — Certificado complementario de protección (CCP) — Reglamento (CE) n.º 469/2009 — Condiciones de obtención de un CCP para medicamentos — Artículo 3, letra a) — Concepto de “producto protegido por una patente de base en vigor” — Artículo 3, letra c) — Concepto de “producto objeto de un CCP” — Criterios de apreciación.#Asunto C-119/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Arrêt de la Cour (troisième chambre) du 19 décembre 2024.#Teva BV et Teva Finland Oy contre Merck Sharp & Dohme LLC et Merck Sharp & Dohme LLC contre Clonmel Healthcare Limited.#Renvoi préjudiciel – Médicaments à usage humain – Certificat complémentaire de protection (CCP) – Règlement (CE) no 469/2009 – Conditions d’obtention d’un CCP pour les médicaments – Article 3, sous a) – Notion de “produit protégé par un brevet de base en vigueur” – Article 3, sous c) – Notion de “produit faisant l’objet d’un CCP” – Critères d’appréciation.#Affaires jointes C-119/22 et C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Breithiúnas na Cúirte (an Tríú Dlísheomra) an 19 Nollaig 2024.#Teva BV agus Teva Finland Oy v Merck Sharp & Dohme LLC agus Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Tarchur chun réamhrialú – Táirgí íocshláinte lena n‑úsáid ag an duine – Deimhniú Forlíontach Cosanta le haghaidh Táirgí Íocshláinte (SPC) – Rialachán (CE) Uimh. 469/2009 – Coinníollacha maidir le SPC a fháil le haghaidh táirgí íocshláinte – Airteagal 3(a) – An coincheap ‘cosaint ag táirge le paitinn bhunúsach atá i bhfeidhm’ – Airteagal 3(c) – An coincheap ‘táirge faoi réir SPC’ – Critéir maidir le measúnú.#Cásanna uamtha C-119/22 agus C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Arrêt de la Cour (troisième chambre) du 19 décembre 2024.#Teva BV et Teva Finland Oy contre Merck Sharp & Dohme LLC et Merck Sharp & Dohme LLC contre Clonmel Healthcare Limited.#Demandes de décision préjudicielle, introduites par le Markkinaoikeus et par la Supreme Court (Irlande).#Renvoi préjudiciel – Médicaments à usage humain – Certificat complémentaire de protection (CCP) – Règlement (CE) no 469/2009 – Conditions d’obtention d’un CCP pour les médicaments – Article 3, sous a) – Notion de “produit protégé par un brevet de base en vigueur” – Article 3, sous c) – Notion de “produit faisant l’objet d’un CCP” – Critères d’appréciation.#Affaires jointes C-119/22 et C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Unionin tuomioistuimen tuomio (kolmas jaosto) 19.12.2024.#Teva BV ja Teva Finland Oy vastaan Merck Sharp & Dohme LLC ja Merck Sharp & Dohme LLC vastaan Clonmel Healthcare Limited.#Markkinaoikeuden ja Supreme Courtin (Irlanti) esittämät ennakkoratkaisupyynnöt.#Ennakkoratkaisupyyntö – Ihmisille tarkoitetut lääkkeet – Lisäsuojatodistus – Asetus (EY) N:o 469/2009 – Lääkkeiden lisäsuojatodistuksen saamisen edellytykset – 3 artiklan a alakohta – Käsite ”voimassa olevalla peruspatentilla suojattu tuote” – 3 artiklan c alakohta – Käsite ”lisäsuojatodistuksen saanut tuote” – Arviointiperusteet.#Yhdistetyt asiat C-119/22 ja C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentenza tal-Qorti tal-Ġustizzja (It-Tielet Awla) tad-19 ta’ Diċembru 2024.#Teva BV u Teva Finland Oy vs Merck Sharp & Dohme LLC u Merck Sharp & Dohme LLC vs Clonmel Healthcare Limited
 .#Talbiet għal deċiżjoni preliminari, imressqa mill-Markkinaoikeus u mis-Supreme Court (l-Irlanda).#Rinviju għal deċiżjoni preliminari – Prodotti mediċinali għall-użu mill-bniedem – Ċertifikat ta’ protezzjoni supplimentari (ĊPS) – Regolament (KE) Nru 469/2009 – Kundizzjonijiet għall-kisba ta’ ĊPS għall-prodotti mediċinali – Artikolu 3(a) – Kunċett ta’ ‘prodott protett minn privattiva bażika fis-seħħ’ – Artikolu 3(c) – Kunċett ta’ ‘prodott li huwa s-suġġett ta’ ĊPS’ – Kriterji ta’ evalwazzjoni.#Kawżi magħquda C-119/22 u C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Domstolens dom (tredje avdelningen) av den 19 december 2024.#Teva BV och Teva Finland Oy mot Merck Sharp & Dohme LLC och Merck Sharp & Dohme LLC mot Clonmel Healthcare Limited.#Begäran om förhandsavgörande från Marknadsdomstolen och Supreme Court (Irland).#Begäran om förhandsavgörande – Humanläkemedel – Tilläggsskydd – Förordning (EG) nr 469/2009 – Villkor för erhållande av tilläggsskydd för läkemedel – Artikel 3 a – Begreppet ’produkt som skyddas av ett gällande grundpatent’ – Artikel 3 c – Begreppet ’produkt för vilken tilläggsskydd har meddelats’ – Bedömningskriterier.#Förenade målen C-119/22 och C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sodba Sodišča (tretji senat) z dne 19. decembra 2024.#Teva BV in Teva Finland Oy proti Merck Sharp & Dohme LLC ter Merck Sharp & Dohme LLC proti Clonmel Healthcare Limited.#Predloga za sprejetje predhodne odločbe, ki sta ju vložili Markkinaoikeus in Supreme Court (Irska).#Predhodno odločanje – Zdravila za uporabo v humani medicini – Dodatni varstveni certifikat (DVC) – Uredba (ES) št. 469/2009 – Pogoji za pridobitev DVC za zdravila – Člen 3(a) – Pojem ‚izdelek varovan z veljavnim osnovnim patentom‘ – Člen 3(c) – Pojem ‚izdelek, ki je predmet DVC‘ – Merila presoje.#Združeni zadevi C-119/22 in C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Rozsudok Súdneho dvora (tretia komora) z 19. decembra 2024.#Teva BV a Teva Finland Oy proti Merck Sharp & Dohme LLC a Merck Sharp & Dohme Corp. proti Clonmel Healthcare Limited.#Návrhy na začatie prejudiciálneho konania, ktoré podali Markkinaoikeus a Supreme Court (Írsko).#Návrh na začatie prejudiciálneho konania – Humánne lieky – Dodatkové ochranné osvedčenie (DOO) – Nariadenie (ES) č. 469/2009 – Podmienky získania DOO na lieky – Článok 3 písm. a) – Pojem ‚výrobok chránený platným základným patentom‘ – Článok 3 písm. c) – Pojem ‚výrobok, na ktorý bolo vydané DOO‘ – Kritériá posúdenia.#Spojené veci C-119/22 a C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Hotărârea Curții (Camera a treia) din 19 decembrie 2024.#Teva BV și Teva Finland Oy împotriva Merck Sharp & Dohme LLC și Merck Sharp & Dohme LLC împotriva Clonmel Healthcare Limited.#Cereri de decizie preliminară formulate de Markkinaoikeus și de Supreme Court (Irlanda).#Trimitere preliminară – Medicamente de uz uman – Certificat suplimentar de protecție (CSP) – Regulamentul (CE) nr. 469/2009 – Condiții de obținere a unui CSP pentru medicamente – Articolul 3 litera (a) – Noțiunea de «produs protejat de un brevet de bază în vigoare» – Articolul 3 litera (c) – Noțiunea de «produs care face obiectul unui CSP» – Criterii de apreciere.#Cauzele conexate C-119/22 și C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Acórdão do Tribunal de Justiça (Terceira Secção) de 19 de dezembro de 2024.#Teva BV e Teva Finland Oy contra Merck Sharp & Dohme LLC e Merck Sharp & Dohme LLC contra Clonmel Healthcare Limited.#Pedidos de decisão prejudicial apresentados pelo Markkinaoikeus e pela Supreme Court (Irlanda).#Reenvio prejudicial — Medicamentos para uso humano — Certificado complementar de proteção (CCP) — Regulamento (CE) n.° 469/2009 — Condições de obtenção de um CCP para os medicamentos — Artigo 3.°, alínea a) — Conceito de “produto protegido por uma patente de base em vigor” — Artigo 3.°, alínea c) — Conceito de “produto objeto de um CCP” — Critérios de apreciação.#Processos apensos C-119/22 e C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Wyrok Trybunału (trzecia izba) z dnia 19 grudnia 2024 r.#Teva BV i Teva Finland Oy przeciwko Merck Sharp & Dohme LLC i Merck Sharp & Dohme LLC przeciwko Clonmel Healthcare Limited.#Wnioski o wydanie orzeczenia w trybie prejudycjalnym złożone przez Markkinaoikeus i przez Supreme Court (Irlandia).#Odesłanie prejudycjalne – Produkty lecznicze stosowane u ludzi – Dodatkowe świadectwo ochronne (DŚO) – Rozporządzenie (WE) nr 469/2009 – Warunki uzyskania DŚO dla produktów leczniczych – Artykuł 3 lit. a) – Pojęcie „produktu chronionego patentem podstawowym pozostającym w mocy” – Artykuł 3 lit. c) – Pojęcie „produktu będącego przedmiotem DŚO” – Kryteria oceny.#Sprawy połączone C-119/22 i C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Arrest van het Hof (Derde kamer) van 19 december 2024.#Teva BV e.a. tegen Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. en Clonmel Healthcare Limited.#Verzoeken van de Markkinaoikeus en de Supreme Court (Ierland) om een prejudiciële beslissing.#Prejudiciële verwijzing – Geneesmiddelen voor menselijk gebruik – Aanvullend beschermingscertificaat (ABC) – Verordening (EG) nr. 469/2009 – Voorwaarden voor de verkrijging van een ABC voor geneesmiddelen – Artikel 3, onder a) – Begrip ‚product beschermd door een van kracht zijnd basisoctrooi’ – Artikel 3, onder c) – Begrip ‚product waarvoor een ABC is verkregen’ – Beoordelingscriteria.#Gevoegde zaken C-119/22 en C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Tiesas spriedums (trešā palāta), 2024. gada 19. decembris.#Teva BV un Teva Finland Oy pret Merck Sharp & Dohme LLC un Merck Sharp & Dohme LLC pret Clonmel Healthcare Limited.#Markkinaoikeus un Supreme Court (Īrija) lūgumi sniegt prejudiciālu nolēmumu.#Lūgums sniegt prejudiciālu nolēmumu – Cilvēkiem paredzētas zāles – Papildu aizsardzības sertifikāts (PAS) – Regula (EK) Nr. 469/2009 – PAS zālēm saņemšanas nosacījumi – 3. panta a) punkts – Jēdziens “produkts, kuru aizsargā spēkā esošs pamatpatents” – 3. panta c) punkts – Jēdziens “produkts, kas ir PAS priekšmets” – Vērtējuma kritēriji.#Apvienotās lietas C-119/22 un C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• 2024 m. gruodžio 19 d. Teisingumo Teismo (trečioji kolegija) sprendimas.#Teva BV ir Teva Finland Oy prieš Merck Sharp & Dohme LLC ir Merck Sharp & Dohme LLC prieš Clonmel Healthcare Limited.#Markkinaoikeus ir Supreme Court (Airija) prašymai priimti prejudicinį sprendimą.#Prašymas priimti prejudicinį sprendimą – Žmonėms skirti vaistai – Papildomos apsaugos liudijimas (PAL) – Reglamentas (EB) Nr. 469/2009 – Vaistų PAL gavimo sąlygos – 3 straipsnio a punktas – Sąvoka „produktas, apsaugotas galiojančiu pagrindiniu patentu“ – 3 straipsnio c punktas – Sąvoka „produktas, kuriam taikomas PAL“ – Vertinimo kriterijai.#Sujungtos bylos C-119/22 ir C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentenza della Corte (Terza Sezione) del 19 dicembre 2024.#Teva BV e Teva Finland Oy contro Merck Sharp & Dohme LLC e Merck Sharp & Dohme LLC contro Clonmel Healthcare Limited.#Domande di pronuncia pregiudiziale proposte dal Markkinaoikeus e dalla Supreme Court (Irlanda).#Rinvio pregiudiziale – Medicinali per uso umano – Certificato protettivo complementare (CPC) – Regolamento (CE) n. 469/2009 – Condizioni di rilascio di un CPC per i medicinali – Articolo 3, lettera a) – Nozione di “prodotto protetto da un brevetto di base in vigore” – Articolo 3, lettera c) – Nozione di “prodotto oggetto di un CPC” – Criteri di valutazione.#Cause riunite C-119/22 e C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• A Bíróság ítélete (harmadik tanács), 2024. december 19.#Teva BV és társai kontra Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. és Clonmel Healthcare Limited.#A Markkinaoikeus (Finnország) és a Supreme Court (Írország) által benyújtott előzetes döntéshozatal iránti kérelmek.#Előzetes döntéshozatal – Emberi felhasználásra szánt gyógyszerek – Kiegészítő oltalmi tanúsítvány (SPC) – 469/2009/EK rendelet – Az SPC megszerzésének feltételei a gyógyszerek esetében – A 3. cikk a) pontja – A „hatályos alapszabadalom oltalma alatt álló termék” fogalma – A 3. cikk c) pontja – Az »SPC tárgyát képező termék« fogalma – Értékelési szempontok.#C-119/22. és C-149/22. sz. egyesített ügyek.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Presuda Suda (treće vijeće) od 19. prosinca 2024.#Teva BV i Teva Finland Oy protiv Merck Sharp & Dohme LLC i Merck Sharp & Dohme LLC protiv Clonmel Healthcare Limited.#Zahtjevi za prethodnu odluku koje je uputio Markkinaoikeus i Supreme Court (Irska).#Zahtjev za prethodnu odluku – Lijekovi za humanu primjenu – Svjedodžba o dodatnoj zaštiti (SDZ) – Uredba (EZ) br. 469/2009 – Uvjeti za dobivanje SDZ-a za lijekove – Članak 3. točka (a) – Pojam ‚proizvod zaštićen temeljnim patentom koji je na snazi’ – Članak 3. točka (c) – Pojam ‚proizvod koji je predmet SDZ-a’ – Kriteriji za ocjenu.#Spojeni predmeti C-119/22 i C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Euroopa Kohtu otsus (kolmas koda), 19.12.2024.#Teva BV ja Teva Finland Oy versus Merck Sharp & Dohme LLC ja Merck Sharp & Dohme LLC versus Clonmel Healthcare Limited.#Eelotsusetaotlused, mille on esitanud Markkinaoikeus ja Supreme Court (Iirimaa).#Eelotsusetaotlus – Inimtervishoius kasutatavad ravimid – Täiendava kaitse tunnistus – Määrus (EÜ) nr 469/2009 – Ravimite täiendava kaitse tunnistuse saamise tingimused – Artikli 3 punkt a – Mõiste „kehtiva aluspatendiga kaitstud toode“ – Artikli 3 punkt c – Mõiste „täiendava kaitse tunnistuse esemeks olev toode“ – Hindamiskriteeriumid.#Liidetud kohtuasjad C-119/22 ja C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Sentencia del Tribunal de Justicia (Sala Tercera) de 19 de diciembre de 2024.#Teva BV y Teva Finland Oy contra Merck Sharp & Dohme LLC y Merck Sharp & Dohme LLC contra Clonmel Healthcare Limited.#Petición de decisión prejudicial planteada por el Markkinaoikeus y por la Supreme Court (Irlanda).#Procedimiento prejudicial — Medicamentos para uso humano — Certificado complementario de protección (CCP) — Reglamento (CE) n.º 469/2009 — Condiciones de obtención de un CCP para medicamentos — Artículo 3, letra a) — Concepto de “producto protegido por una patente de base en vigor” — Artículo 3, letra c) — Concepto de “producto objeto de un CCP” — Criterios de apreciación.#Asunto C-119/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Απόφαση του Δικαστηρίου (τρίτο τμήμα) της 19ης Δεκεμβρίου 2024.#Teva BV και Teva Finland Oy κατά Merck Sharp & Dohme LLC και Merck Sharp & Dohme LLC κατά Clonmel Healthcare Limited.#Αιτήσεις του Markkinaoikeus και του Supreme Court (Ιρλανδία)για την έκδοση προδικαστικής αποφάσεως.#Προδικαστική παραπομπή – Φάρμακα που προορίζονται για ανθρώπινη χρήση – Συμπληρωματικό πιστοποιητικό προστασίας (ΣΠΠ) – Κανονισμός (ΕΚ) 469/2009 – Όροι χορήγησης ΣΠΠ για τα φάρμακα – Άρθρο 3, στοιχείο αʹ – Έννοια του “προϊόντος που προστατεύεται με ισχύον κύριο δίπλωμα ευρεσιτεχνίας” – Άρθρο 3, στοιχείο γʹ – Έννοια του “προϊόντος που αποτελεί αντικείμενο ΣΠΠ” – Κριτήρια εκτιμήσεως.#Συνεκδικασθείσες υποθέσεις C-119/22 και C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Urteil des Gerichtshofs (Dritte Kammer) vom 19. Dezember 2024.#Teva BV und Teva Finland Oy gegen Merck Sharp & Dohme LLC und Merck Sharp & Dohme LLC gegen Clonmel Healthcare Limited.#Vorabentscheidungsersuchen des Markkinaoikeus und des Supreme Court (Irland).#Vorlage zur Vorabentscheidung – Humanarzneimittel – Ergänzendes Schutzzertifikat (ESZ) – Verordnung (EG) Nr. 469/2009 – Bedingungen für die Erteilung eines ESZ für Arzneimittel – Art. 3 Buchst. a – Begriff ‚durch ein in Kraft befindliches Grundpatent geschütztes Erzeugnis‘ – Art. 3 Buchst. c – Begriff ,Erzeugnis, für das ein ESZ erteilt wurde‘ – Beurteilungskriterien.#Verbundene Rechtssachen C-119/22 und C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Domstolens dom (Tredje Afdeling) af 19. december 2024.#Teva BV og Teva Finland Oy mod Merck Sharp & Dohme LLC og Merck Sharp & Dohme LLC mod Clonmel Healthcare Limited.#Anmodninger om præjudiciel afgørelse indgivet af Markkinaoikeus og Supreme Court (Irland).#Præjudiciel forelæggelse – humanmedicinske lægemidler – supplerende beskyttelsescertifikat – forordning (EF) nr. 469/2009 – betingelser for udstedelse af et supplerende beskyttelsescertifikat for lægemidler – artikel 3, litra a) – begrebet »produkt beskyttet ved et grundpatent, der er i kraft« – artikel 3, litra c) – begrebet »produkt, der er genstand for et supplerende beskyttelsescertifikat« – bedømmelseskriterier.#Forenede sager C-119/22 og C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Rozsudek Soudního dvora (třetího senátu) ze dne 19. prosince 2024.#Teva BV a Teva Finland Oy v. Merck Sharp & Dohme LLC a Merck Sharp & Dohme LLC v. Clonmel Healthcare Limited.#Žádosti o rozhodnutí o předběžné otázce podané Markkinaoikeus a Supreme Court (Irlande).#Řízení o předběžné otázce – Humánní léčivé přípravky – Dodatkové ochranné osvědčení (DOO) – Nařízení (ES) č. 469/2009 – Podmínky pro získání DOO pro léčivé přípravky – Článek 3 písm. a) – Pojem ‚výrobek chráněný platným základním patentem‘ – Článek 3 písm. c) – Pojem ‚výrobek, který je předmětem DOO‘ – Kritéria pro posouzení.#Spojené věci C-119/22 a C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Решение на Съда (трети състав) от 19 декември 2024 г.#Teva BV и др. срещу Merck Sharp & Dohme LLC, anciennement Merck Sharp & Dohme Corp. и Clonmel Healthcare Limited.#Преюдициални запитвания, отправени от Markkinaoikeus и Supreme Court (Ирландия).#Преюдициално запитване — Лекарствени продукти за хуманна употреба — Сертификат за допълнителна закрила (СДЗ) — Регламент (ЕО) № 469/2009 — Условия за получаване на СДЗ за лекарствените продукти — Член 3, буква а) — Понятие за продукт, защитен с основен патент, който е в сила — Член 3, буква в) — Понятие за продукт, предмет на СДЗ — Критерии за преценка.#Съединени дела C-119/22 и C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  judgment · 19 December 2024 · Judgment of the Court (Third Chamber) of 19 December 2024.#Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited.#Requests for a preliminary ruling from the Markkinaoikeus and the Supreme Court (Ireland).#Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of ‘product protected by a basic patent in force’ – Article 3(c) – Concept of ‘product the subject of an SPC’ – Criteria for assessment.#Joined Cases C-119/22 and C-149/22.

  DownloadOpen at official source

• Gewijzigde motie van het lid Diederik van Dijk over in kaart brengen hoeveel stellen afzien van relatietherapie omdat de kosten hiervan voor hen te hoog zijn (t.v.v. 25424-719)

  Motie (gewijzigd/nader) · 18 December 2024 · Gewijzigde motie van het lid Diederik van Dijk over in kaart brengen hoeveel stellen afzien van relatietherapie omdat de kosten hiervan voor hen te hoog zijn (t.v.v. 25424-719)

  DownloadOpen at official source

• Dataverwerking in de ggz

  Brief regering · 18 December 2024 · Dataverwerking in de ggz

  DownloadOpen at official source

• Reactie op verzoek commissie over notitie 'Toegepast hbo-psychologen dragen bij aan het reduceren van kosten en arbeidsmarkttekorten in de ggz' van NBTP

  Brief regering · 18 December 2024 · Reactie op verzoek commissie over notitie 'Toegepast hbo-psychologen dragen bij aan het reduceren van kosten en arbeidsmarkttekorten in de ggz' van NBTP

  DownloadOpen at official source